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Abstract
Introduction: Lupus nephritis (LN) is a severe and frequent manifestation of systemic lupus erythematosus (SLE).
Early detection of initial renal manifestations and relapses during follow-up is pivotal to prevent loss of renal
function. Apart from renal biopsies, current urinary and serological diagnostic tests fail to accurately demonstrate
the presence of active LN. Previously, we demonstrated that effector memory T-cells (CD45RO+CCR7-;TEM) migrate
into the urine during active LN. The objective of this study was to assess the diagnostic value of urinary T-cells in
comparison with traditional markers of active LN.
Methods: T-cells in the urine during active LN and remission were investigated. Twenty-two, in most cases
biopsy-proven, active LN patients and 24 SLE patients without active LN were enrolled and serial measurements
were performed in 16 patients.
Results: Analysis of the urinary sediment in active renal disease showed an increased number of CD8+ T-cells and
absence of these cells during remission. Enumerating T-cell counts in LN patients with a history of renal
involvement was a superior marker of active LN in comparison to traditional markers, such as proteinuria and
s-creatinine.
Conclusions: In conclusion, urinary T-cells, in particular CD8+ T cells, are a promising marker to assess renal activity
in LN patients, in particular in those with prior renal involvement.
Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by manifestations in multiple
organs. Inflammation of the kidneys, in particular, is
associated with an unfavorable prognosis [1,2]. Although
the precise pathogenesis of lupus nephritis (LN) has not
been fully elucidated, kidney infiltrating T-cells seem to
contribute to the inflammatory pathology of LN [3].
Evaluation for LN includes dipstick and urine sedi-
ment analysis, urinary protein and creatinine excretion,
determination of serum creatinine and assessment of
serological markers, such as anti-dsDNA antibody titers
and C3 and C4 levels [4]. The combination of these
markers is a powerful measure for the detection of
active renal manifestations of SLE. However, in clinical
practice, traditional clinical markers for renal
involvement, such as proteinuria, not always discrimi-
nate between active and inactive disease, in particular in
patients with a recent history of LN [5]. In these
patients persistent proteinuria often limits the informa-
tion of this test to detect renal flares or remission. This
is due to the fact that proteinuria might reflect both glo-
merular damage and renal activity. For these patients,
strict guidelines defining renal flares based on laboratory
information are lacking [6]. Therefore, renal biopsies are
crucial and are still the gold standard to assess renal dis-
ease and to define the histo-pathologic class of LN [7].
This invasive approach is associated with a risk of bleed-
ing and repeated renal biopsies are not always applicable
in daily clinical practice in patients with SLE.
Thus, novel non-invasive urinary markers seem to be
an attractive goal to detect renal flares in LN. Several
studies demonstrated the presence of mononuclear cells
in urine of patients with active IgA nephropathy, LN
and Wegener’s granulomatosis [8-10]. Recently, we
reported an increase of urinary TEM-cells (CD45RO
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+CCR7-) in patients with active LN [11]. Remarkably,
these cells were almost absent in healthy controls and
random lupus patients without active LN. These data
suggest that measuring urinary T-cells might also be
helpful in discriminating active LN versus patients with
a recent history of LN but without current active renal
disease. Therefore, in a serial cohort of LN patients tra-
ditional clinical markers and urinary T-cell counts were
analyzed at the time of active and inactive renal disease
to evaluate the significance of urinary T-cell measure-
ments for assessing renal activity. The present data sug-
gest that measuring urinary T-cells, in particular CD8+
T cells, might be an additional diagnostic tool to deter-
mine renal disease activity, particularly in patients with
a recent history of lupus nephritis.
Materials and methods
Study population
A total of 46 SLE patients fulfilling at least four of the
American College of Rheumatology revised criteria for
SLE were enrolled in this study [12]. Twenty-four
patients, including 14 patients without a history of renal
involvement, have been described before [11]. Twenty-
two patients were enrolled with active LN (Table 1).
Disease activity was assessed by SLEDAI (SLE Disease
Activity Index) and active SLE was defined as a SLEDAI
score >4. Mean disease activity for active LN patients
was 13 ± 3 (Table 1). Median (range) anti-dsDNA titers
were 230 (3 to 1,000 E/ml), median C3 and C4 were
0.55 g/l (0.05 to 1.03) and 0.14 g/l (0.04 to 0.30).
Twenty-four 24 hour-proteinuria was 2.8 ± 3.3 g/l
among active LN patients. Active LN was defined by at
least two of the following items: (i) new onset protei-
nuria >0.5 g/24 h, (ii) an active urinary sediment repre-
senting glomerular injury and (iii) a renal biopsy
providing evidence of active lupus nephritis (n = 21)
(Table 1). According to the International Society of
Nephrology (ISN) classification, histopathology showed
class II (n = 1), class III (n = 9), class III/V (n = 1), class
IV (n = 10) or unclassified LN (n = 1) in the present
cohort. The mean activity index (AI) according to Aus-
tin was 4.6 ± 2.6. All active LN patients fulfilled the
renal BILAG-2004 category A criteria and, subsequently,
received an escalation of immunosuppressive treatment
[13]. Sixteen patients (class II (n = 1), class III (n = 7),
class IV (n = 8)) were analyzed twice, both during active
renal disease and inactive renal disease. The time
between the visits was 14 ± 4 months. Inactive renal dis-
ease was defined as renal BILAG-2004 category B or C.
Thus, in these patients renal function was stable or
improving and there was no need to escalate or change
maintenance therapy. Medication of patients with active
and inactive LN is shown in Table 2. Informed written
consent was obtained from patients after approval of the
study by the Medical Ethics Committee of the Univer-
sity Medical Center Groningen. The study was con-
ducted according to the ethical guidelines of our
institution and the Declaration of Helsinki.
Materials
EDTA-blood and fresh urine samples were collected
from patients. Urine samples from patients which were
Table 1 Baseline characteristics of LN patients included in the study (n = 46)
Active LN Without active LN
History of LN No history of LN
Total number 22 10 14
Women/men 19/3 7/3 13/1
Age (years, mean ± SD) 35 ± 10* 46 ± 14 37 ± 10
SLEDAI (mean ± SD) 13 ± 3 **, ## 3 ± 2 3 ± 3
Anti-dsDNA, E/ml (median, range) 230 (3 to 1,000)*, ## 5 (3 to 432) 81 (3 to 1,000)
C3 g/l (median, range) 0.54 (0.05 to 1.03)**, ## 1.13 (0.54 to 1.48) 0.99 (0.31 to 1.43)
C4 g/l (median, range) 0.08 (0.03 to 0.48)* 0.23 (0.04 to 0.30)$ 0.12 (0.05 to 0.24)
Previous biopsy proven LN (yes/no) 9/13 10/0 0/14
Serum creatinine µmol/l 94 ± 78# 80 ± 26 62 ± 13
Urinary analysis
Proteinuria g/24 h (mean ± SD) 2.8 ± 3.2**, ## 0.3 ± 0.3$,$ 0.0 ± 0.1
Dysmorphic erythrocytes in % 36 % 0.% 0.%
CD4+T-cells/ml (median, range) 128 (0 to 1,250)**, ## 9 (0 to 63) 0 (0 to 136)
CD8+T-cells/ml (median, range) 177 (0 to 1,388)**, ## 13 (0 to 118) 17 (0 to 92)
The patients were sub-grouped into biopsy proven LN (n = 22) and patients without active LN (n = 24). The patients without active LN were further sub-grouped
into patients with biopsy proven LN in the past (n = 10) and patients without renal involvement (n = 14). Significant differences between patients with active LN
and patients with biopsy proven LN in the past without current activity are indicated (P <0.05 = *, P <0.005 = **). Significant differences between active LN and
patients without renal involvement are indicated (P <0.05 =#, P <0.005 =##). Significant differences between patients with biopsy proven LN in the past without
current activity and patients without renal involvement are indicated (P <0.05 =$, P <0.005 =$$).
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nitrite positive on a dip stick test or with proof of bac-
terial contamination in the sediment were excluded.
Percentages and absolute counts of CD4+ and CD8+
T-cells were assessed immediately after sampling by four-
color flow cytometry in blood and urine samples. Paraffin-
embedded sections of renal biopsy specimens obtained
from 22 patients were included in the present study.
Antibodies
The following antibodies were used in flow cytometry:
phycoerythrin (PE)-conjugated anti-CCR7 (clone 3D12),
fluorescein (FITC)-conjugated anti-CD45RO (clone
UCHL-1), peridin-chlorophyll (PerCP)-conjugated anti-
CD4 (clone SK3), allophycocyanin (APC)-conjugated
anti-CD3 (clone UCHT1), MultiTEST™ four-color anti-
bodies (CD3-FITC, CD8-PE, CD45-PerCP and CD4-
APC), and isotype matched control antibodies of irrele-
vant specificity. All were purchased from Becton-Dickin-
son ((BD), Amsterdam, The Netherlands).
Sample preparation and flow cytometry
Immediately after voiding, urine was diluted 1:1 with
cold phosphate-buffered saline (PBS) and processed as
described before. Briefly, isolated mononuclear cells
were resuspended in wash-buffer (1% BSA in PBS) and
mixed with appropriate concentrations of anti-CD45RO-
FITC, anti-CCR7-PE, anti-CD4-PerCP and anti-CD3-
APC for 15 minutes at room temperature in the dark.
In parallel, blood samples were labeled with the afore-
mentioned monoclonal antibodies. Afterwards, cells
were successively treated with 2 ml diluted FACS lysing
solution (BD, Amsterdam, The Netherlands) for 10 min-
utes and samples were washed twice in wash-buffer and
immediately analyzed by flow cytometry. Four-color
staining was analyzed on FACS-Calibur (BD, Amster-
dam, The Netherlands) and data were collected for 105
events for each sample and plotted using Win-List soft-
ware package (Verity Software House Inc., Topsham,
ME, USA). Positively and negatively stained populations
were calculated by quadrant dot-plot analysis, as deter-
mined by the isotype controls.
Quantification of effector memory T-cells
T-cells were quantified in urine using TruCOUNT™
Tubes (BD, Amsterdam, The Netherlands). In brief, 20
µl of MultiTEST™ four-color antibodies (CD3 FITC,
CD8 PE, CD45 PerCP and CD4 APC) and 50 µl of sam-
ple (urine or blood) were added to bead-containing Tru-
COUNT™ tubes. The cell suspension was processed
and analyzed as described elsewhere. Afterwards, the
absolute counts for TEM cells in 1 ml urine were calcu-
lated as described before [8].
Analysis and scoring of renal biopsies
Biopsies taken at the time of analysis of blood and urine
samples were processed. All biopsies were reviewed and
classified by an experienced nephropathologist (MvD)
according to the revised criteria for LN. The AI and
chronicity index (CI) were calculated for each specimen
with maximum scores of 24 for the AI and 12 for the
CI. For this study, methenaminesilver-stained slides
(with HE-counterstaining), H&E and periodic acid-Schiff
(PAS) stained slides were used.
The assessment was completed by determining the
ISN/RPS2003 classification and activity and chronicity
indices for LN [14]. For these aspects of the assessment,
the definitions of the classification systems and the
activity and chronicity indices were used.
Immunohistochemistry staining
All specimens were fixed in 10% neutral buffered forma-
lin and paraffin embedded. Five-micrometer-thick
Table 2 Use of immunosupressive drugs in patients with active lupus nephritis (LN) and inactive LN patients
Active LN Inactive LN P-value
Total number 22 24
Treatment, n
None 8 3 0.038
Glucocorticoids 10 13
Median dose (range), dose (mg/day) 5 (2.5 to 15) 5 (1.25 to 10)
Immunosupressive/immunomodulating, n
Hydroxychloroquine 9 8
Median dose (range), users (mg/day) 400 (200 to 600) 400 (200 to 600)
Methotrexate 1 2
Median dose (range), users (mg/week) 7.5 13.75 (12.5 to 15.0)
Azathioprine 4 8
Median dose (range), users (mg/day) 100 (75 to 150) 112.5 (75 to 150)
MMF 1 3
Median dose (range), users (mg/day) 2,000 3,000 (2,000 to 3,000)
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sections were deparaffinized in xylene and rehydrated in
a series of different concentrations of ethanol. EDTA
buffer, pH 8.2, for heat-induced epitope retrieval was
applied for 1 h, followed by neutralization of endogen-
ous peroxidase with 0.3% H2O2. Incubation with a
monoclonal mouse anti-human CD8 (DAKO, Glostrup,
Denmark) was performed. Next, sections were washed
and incubated with a HRP-conjugated secondary anti-
body (Envison™, DAKO, Glostrup, Denmark) for 30
minutes at room temperature. A DAB substrate was
used for visualization. Washing with PBS was performed
after each incubation step. CD4 (Roche/Ventana Medi-
cal Systems Inc., Oro Valley, AZ, USA)) was performed
in the Benchmark Ultra (Roche/Ventana) with citrate
buffer heat inducted antigen retrieval and detected with
the ultraView Universal DAB detection Kit (Roche/Ven-
tana). Finally, the slides were counterstained with hema-
toxylin and mounted with Kaiser’s glycerine gelatin
(Merck, Darmstadt, Germany).
Cells were separately counted for the interstitium and
glomeruli. Cells with positive staining for CD8 and CD4
were counted per high powerfield (40x magnification).
The average value was calculated for each biopsy.
Statistical analysis
Based on our prior findings regarding urinary CD8+
T-cells in active (mean 287 ± 220 cells/ml) versus inac-
tive LN patients (mean 22 ± 28 cells/ml) [11], we con-
ducted a power analysis using G*Power 3.1.5. A total
sample size of n = 18 achieves 90% power to detect this
difference of CD8+ T-cells between the mean of both
groups (effect size: 1.69) using a two-sided hypothesis
test with a significance level (alpha) of 0.05.
Results were presented as median (range) or mean ±
SD and the nonparametric Mann-Whitney U-test was
used for comparison of values between groups. Paired
samples were tested using the Wilcoxon signed rank
test. Correlation with disease activity was assessed using
Spearman’s rank correlation coefficient. Receiver opera-
tor curve (ROC) analysis was performed for urinary
T-cells and proteinuria to evaluate the discriminative
power between patients with active vs. inactive LN. All
analyses were performed using GraphPad Prism 5.0
(GraphPad Software Inc., La Jolla, CA, USA). P-values
less than 0.05 were regarded as statistically significant.
Results
CD8+ T-cell count discriminates between active and
inactive LN
We detected T-cells in the urine in 21 active LN
patients out of the 22. Only one active LN patient pre-
sented without urinary T-cells, which means a sensitivity
of 95%. The median (range) count of urinary CD4+
T-cells was significantly increased in active LN patients
in comparison to inactive LN patients (128 (0 to 1,250
cells/ml) vs. 5 (0 to 136 cells/ml), respectively (P
<0.0001)) (Table 1). The median (range) count of urin-
ary CD8+ T-cells was also significantly increased in
active LN patients in comparison to inactive LN patients
(177 (0 to 1,388 cells/ml) vs. 14 (0 to 118 cells/ml),
respectively (P <0.0001)). The median urinary CD8
+/CD4+ ratio was 1.7, suggesting that predominantly
CD8+ T-cells are migrating into the kidney.
ROC analysis revealed that the urinary CD4+ and CD8+
T-cell count discriminates between active and inactive
LN (area under the curve (AUC) 0.92 and 0.93, respec-
tively). Urinary T-cell counts were somewhat weaker
indicators for active renal disease than proteinuria (AUC
0.97) but superior to s-creatinine (AUC 0.60). There was
no significant correlation between urinary CD4+ or CD8+
T-cell counts and AI or CI, respectively.
Decrease of urinary T-cell counts after induction of
remission
Urine specimens of 16 patients were analyzed at the time
of active renal disease and remission (Δ t = 14 ± 4
months) to assess intra-individual changes in urinary
T-cell counts. Fifteen of these patients were active at
baseline and treated with induction therapy for LN. One
patient was in renal remission at baseline and had a
biopsy proven relapse during follow-up. Urinary CD4+
T-cell counts decreased significantly from 125 (0 to 569
cells/ml) to 0 (0 to 82 cells/ml, P = 0.001, Figure 1) from
active renal disease into remission. CD8+ T-cells
decreased from 124 (0 to 841 cells/ml) to 0 (0 to 33
cells/ml, P <0.0001). SLEDAI scores decreased signifi-
cantly from 13 ± 3 to 3 ± 2 (P <0.0001).
In accordance with changes in disease activity anti-
dsDNA titers decreased significantly from 230 (3 to 1,000
E/ml) to 29 (3 to 200 E/ml, P = 0.0006). C3 complement
levels increased from 0.55 (0.05 to 0.79 g/l) during active
LN to 0.90 (0.74 to 1.41 g/l, P = 0.0005) during quiescent
renal disease. C4 complement levels increased from 0.07
(0.03 to 0.48 g/l) during active LN to 0.15 (0.06 to 0.30
g/l, P = 0.008) during quiescent renal disease. Serum
creatinine levels remained stable at 79 ± 40 µmol/l in
active LN patients as compared to 71 ± 23 µmol/l in
inactive LN patients. The 24-h urinary protein excretion
decreased significantly from 3.1 ± 3.6 g/l to 0.7 ± 1.0 g/l
(P = 0.005) (Figure 1A-E). Importantly, although all para-
meters (except serum creatinine) significantly changed
when patients turned from active into inactive LN, there
remained considerable overlap. For example, 5 out of 16
patients with inactive lupus nephritis had 24-h urinary
protein excretion levels of >0.5 g/l. In contrast, urinary
CD8+ T-cell counts in all patients with inactive LN could
be discriminated from those during active LN as no over-
lap in urinary CD8+ T-cells occurred.
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T-cell count discriminates between active and inactive LN,
independent of a history of LN
To assess the additional value of urinary T-cell counts
to discriminate active from inactive LN, in particular in
patients with a history of biopsy proven LN, we subdi-
vided the cohort of patients without active LN in two
groups, one group without renal involvement (n = 14)
and one group with patients with a history of LN (n =
10). Proteinuria was significantly increased in patients
with a history of LN as compared to patients without
LN (0.3 ± 0.3 g/24 h vs. 0.0 ± 0.1 g/24 h, P = 0.002).
There was no difference in serum creatinine levels
between both groups.
ROC analysis (Figure 2A) shows that proteinuria is an
excellent marker to discriminate patients with active LN
from patients without renal involvement (AUC 0.99).
The discriminative power was somewhat lower in
patients with active LN versus inactive LN patients
(AUC 0.94) (Figure 2B). In contrast, in this cohort the
discriminative power of urinary T-cell counts was com-
parable with respect to urinary CD4+ T-cells (AUC
0.92) and CD8+ T-cells (AUC 0.92).
T-cells in renal biopsies
To determine the presence and localization of CD8+ T-
cells and CD4+ T-cells in renal biopsies, immunohisto-
chemistry staining with anti-CD8 and anti-CD4 was
performed.
T-cells were present in all except one renal biopsy
investigated. The mean amount of CD8+ T-cells was 5.0
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Figure 1 Laboratory data of serially analyzed LN patients (n = 16) during active and inactive LN. Intra-individual comparison between
levels of C3, C4, anti-dsDNA titres, proteinuria, s-creatinine, urinary CD4+ and CD8+ T-cell counts in lupus nephritis (LN) patients (n = 16) during
active and inactive LN is shown in sections A-G. The time interval between these two assessments was 14 ± 4 months. P-values were calculated
using the nonparametric Wilcoxon signed rank test. Significant differences are indicated (P <0.05 = *, P <0.005 = **).
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± 4.3 cells/high power field. This was significantly
higher than the mean amount of CD4+T-cells (2.4 ± 2.8
cells/high power field; P = 0.006). Urinary CD8+ T-cells
did not correlate significantly with the amount of kidney
infiltrating CD8+ T-cells (r = 0.28, P = 0.29). The num-
ber of urinary CD4+ T-cells correlated significantly with
the number of CD4+ T-cells/high power field in these
renal biopsies (r = 0.53, P = 0.04). There was no signifi-
cant correlation between T-cell numbers in the urine
and renal AI (data not shown).
Discussion
The present study, in accordance with our preliminary
data, demonstrates that urinary effector T-cells are
increased during flares of LN. Urinary T-cells with an
effector-memory phenotype can be detected in almost
all active LN patients. Several studies demonstrated an
increased number of kidney infiltrating T-cells in LN
patients [15-18]. In these reports the authors investi-
gated chemokine receptor expression of T-cells to
explain the underlying mechanism of T-cell recruitment.
They found, in particular, a selective accumulation of
CCR4+ and CXCR3+ T-cells accompanied by a decrease
of these subsets in the peripheral blood [15,17]. A study
by Enghard et al. showed that CD4+CXCR3+ T-cells are
infiltrating into the inflamed kidneys and can be
detected in the urine during acute renal flares [17]. In
agreement with our data, CD4+ T-cells were increased
in active renal disease. However, our findings show that
CD8+ T-cell counts seem to differentiate more accu-
rately between active and inactive renal disease. Besides,
the aforementioned studies did not include serial mea-
surements in representative cohorts of SLE patients.
In the context of the clinical course of LN, T-cell
recruitment and migration might be restricted to active
disease. In order to demonstrate that urinary T-cells are
specific for renal activity in SLE we assessed T-cell
counts in a cohort with active LN and a cohort of
patients without active LN, including patients with a
history of LN. A significantly increased number of urin-
ary T-cells was detectable during active LN. This was
especially true for the CD8+ T-cell count, as no overlap
in CD8+ T-cell counts was observed between active and
inactive LN patients. This seems to reflect the histo-
pathological findings at least to a certain extent in active
renal lupus nephritis, which is supported by the pre-
sence of CD8+ and an intra-renal CD4+/ CD8+ ratio <1.
Besides, we have to admit that the specificity and power
of this new tool is limited by the lack of kidney biopsies
from inactive lupus nephritis patients due to ethical
reasons.
The present data suggest that measuring urinary T-
cells could serve as an additional diagnostic marker for
LN. ROC analysis was performed for urinary T-cells and
proteinuria to evaluate their power to discriminate
between active LN patients and inactive LN. This analy-
sis showed that 24 h proteinuria (AUC 0.97) is still
superior to distinguish between active LN patients and
patients without active LN (Figure 2). However, the pre-
sented subanalysis reveals also that the discriminative
power is related to renal involvement. Proteinuria discri-
minates sharply between active LN patients and patients
=CD4+ =CD8+ =proteinuria =s-crea 
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Figure 2 Receiver operator curve (ROC) analysis for proteinuria (g/24 h), serum creatinine, urinary CD4+ and CD8+ T-cells comparing
SLE patients with active renal disease (n = 22) vs. patients without renal involvement (n = 14) (A). The same parameters are shown
comparing patients with active LN (n = 22) vs. patients with a history of LN but without current renal activity (B). The area under the curve
(AUC) is shown for all parameters.
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without renal involvement (AUC 0.99). However, the
diagnostic value decreases in patients with a history of
LN (AUC 0.94).
More difficulties exist in assessing renal activity in
patients with recently active LN. Therefore, we analyzed
traditional renal markers in our follow-up cohort. In
these patients, persistent proteinuria is a frequent find-
ing and a predictor of chronic kidney disease [19].
Although a significant decrease of proteinuria could be
observed in this cohort, almost 30% of patients were
still excreting protein at the time of remission (≥0.5 g/l
in 24 h). This limits in these patients the diagnostic
value of proteinuria for the early detection of renal flares
whereas CD8+ T-cell counts sharply discriminates
between these groups (P <0.0001).
Despite the suboptimal predictive value of proteinuria
for renal flares, the combined evaluation of urinary pro-
tein excretion and microscopic urine analysis is still the
routine standard to assess renal disease activity in LN
[20]. In some cases, assessment of urinary protein excre-
tion is not conclusive, especially in patients with long-
standing renal involvement and persistent proteinuria.
The presence of an active urinary sediment, in particular
the presence of dysmorphic erythrocytes, then is a
necessary requirement. However, in our experience, the
supplementary information of microscopic urine analysis
is somewhat limited. The quality of the urinary speci-
mens is often inappropriate and microscopic urine ana-
lysis revealed only in a restricted number (8 out of 22)
of biopsy proven active LN patients an active sediment.
Additionally, clear guidelines and definitions of active
LN in patients with a history of renal injury are lacking
[21].
Conclusions
In conclusion, the present study strengthens our preli-
minary observation that urinary effector T-cells are
increased during renal flares of LN. Moreover, these
data suggest an additional diagnostic role of measuring
urinary T-cells. This analysis will be especially helpful in
LN patients with a recent history of LN. This relates to
the fact that persistent proteinuria is a frequent observa-
tion which limits the use of this marker for the judge-
ment of renal activity. Measuring urinary CD8+ T-cells
helps to discriminate between active and inactive LN.
To introduce this test into routine diagnostics, further
studies are needed to confirm these results in a larger
cohort of biopsy-proven LN patients.
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